- Low-dose thalidomid in refractory and relapsing multiple myeloma2007 | First Faculty of Medicine
- Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study2023 | First Faculty of Medicine
- Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study2017 | First Faculty of Medicine
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma2015 | Faculty of Medicine in Hradec Králové
- Lenalidomide in the treatment of refractory, or relapsed multiple myeloma2012 | Faculty of Medicine in Hradec Králové
- Low-dose thalidomid in refractory and relapsing multiple myeloma +12007 | Faculty of Medicine in Hradec Králové
- Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma2019 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data2020 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment2017 | First Faculty of Medicine
- Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data2020 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial2021 | First Faculty of Medicine
- Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis2022 | First Faculty of Medicine
- Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis2022 | First Faculty of Medicine
- Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma2016 | Publication without faculty affiliation
- Bortezomib (velcade) for refractory/relapsed multiple myeloma-results of Czech myeloma group (CMG) and Slovak myeloma society (SMS)Publication without faculty affiliation
- Komentář ke studii (Karfilzomib, lenalidomid a dexamethason v léčbě pacientů s relabujícím mnohočetným myelomem - studie ASPIRE)2016 | First Faculty of Medicine
- Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study2018 | Faculty of Medicine in Hradec Králové
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. PX-171-009Publication without faculty affiliation
- Guidelines for Multiple Myeloma 2012: status of lenalidomide in the treatment of refractory / relapsed disease2012 | Faculty of Medicine in Hradec Králové
- Lenalidomide in the treatment of multiple myeloma +12009 | Faculty of Medicine in Hradec Králové
- Lenalidomide in the treatment of multiple myeloma2009 | First Faculty of Medicine
- Experience with the use of bortezomib (Velcade) in the Czech Republic since 20042011 | Faculty of Medicine in Hradec Králové
- Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma2018 | Faculty of Medicine in Hradec Králové
- Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies2023 | First Faculty of Medicine
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study2022 | First Faculty of Medicine